| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00265382 Details | 2021-03-03 Interventional | 3 | 221 | Ziprasidone Schizophrenia | Please see Detailed Description for termination reason. The AE tables were amended to incorporate previously unreported AEs that were found during an independent audit and verified by the investigators. | |||
| NCT00163241 Details | 2021-03-03 Interventional | 3 | - | Celecoxib Osteoarthritis Osteoarthritis,… | Please see detailed description for termination reason. - | |||
| NCT03811951 Details | 2021-03-02 Interventional | 2 | 4 | Insulin Smoking Cessati… | Different study initiation - | |||
| NCT02255461 Details | 2021-03-02 Interventional | 1 | 35 | Palbociclib Astrocytoma Central Nervous… Choroid Plexus … Glioblastoma Gliosarcoma Medulloblastoma Meningioma Neoplasms Neoplasms, Neur… Nervous System … Neuroectodermal… Neuroectodermal… Oligodendroglio… Pinealoma Recurrence Childhood Choro… Childhood Epend… Childhood Grade… Childhood High-… Childhood High-… Childhood Medul… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… Recurrent Child… | Data for the primary objectives is complete and the MTD identified in Stratum II. - | |||
| NCT03474510 Details | 2021-03-01 Interventional | 4 | 0 | Bupivacaine Ropivacaine Pain, Postopera… Shoulder Osteoa… | Investigator Decision - | |||
| NCT02684617 Details | 2021-03-01 Interventional | 1 | 75 | Pembrolizumab Hematologic Neo… rrCLL rrDLBCL rrMM | Business Reasons - | |||
| NCT03832673 Details | 2021-02-26 Interventional | 2 | 0 | Pembrolizumab Urinary Bladder… Muscle-invasive… | Regolatory National Agency (AIFA) not approved - | |||
| NCT01714817 2012-000714-11 Details | 2021-02-26 Interventional | 3 | 695 | Abatacept Mycophenolic Ac… Prednisone Lupus Nephritis Nephritis | Inability to meet protocol objectives. Study terminated early after review of Year 1 data. Only Year 2/LTE data captured within blind was analyzed. Outcomes related to renal responses were not calculated due to lack of data caused by the early termination. | |||
| NCT01334047 Details | 2021-02-26 Interventional | 1/2 | 5 | Vaccines Carcinoma, Ovar… Ovarian Neoplas… Recurrence Recurrent Epith… | The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol
with an expected more efficient vaccine is currently being written. - | |||
| NCT00961844 2008-006253-41 Details | 2021-02-26 Interventional | 1/2 | 15 | Temozolomide Melanoma Metastatic Mali… | Logistical problems - | |||
| NCT00864097 2009-009318-41 Details | 2021-02-26 Interventional | 3 | 607 | Diclofenac Tanezumab Osteoarthritis Osteoarthritis,… | See termination reason in detailed description. Due to United States Food and Drug Administration (FDA) imposed clinical hold, further study drug dosing was stopped prematurely and study was terminated. | |||
| NCT02687269 Details | 2021-02-25 Interventional | 4 | 0 | Ranolazine Myocardial Stun… | Inability to produce placebo tablets similar to the drug tested - | |||
| NCT02687100 Details | 2021-02-25 Interventional | 4 | 0 | Beclomethasone Pharyngitis Anesthesia, End… | Due to instillation site of the cortisone and the development of the related SARS-Cov2
infection, it was preferred to terminate the trial and develop it again without beclomethasone - | |||
| NCT03814148 Details | 2021-02-24 Interventional | 3 | 0 | Indapamide Hypertension Arterial Hypert… | The design of this protocol was rewritten due to regulatory recommendations. - | |||
| NCT01087203 Details | 2021-02-24 Interventional | 2 | 73 | Tanezumab Diabetic Neurop… Peripheral Nerv… Diabetic Periph… | See termination reason in detailed description. This study was terminated following a United States (US) Food and Drug Administration (FDA) partial clinical hold. | |||
| NCT04084158 Details | 2021-02-23 Interventional | 2 | - | Albumin-Bound P… Paclitaxel Carcinoma Carcinoma, Squa… Esophageal Squa… | combination arm delevelped significant poor prognosis - | |||
| NCT03224585 Details | 2021-02-23 Interventional | 2 | 5 | Interleukin 1 R… Pericarditis Acute Pericardi… | Study was terminated because dramatic benefits seen during the first 24 hours of drug
administration combined with COVID restrictions on research activities suggested it was both
unethical and unnecessary to complete the planned enrollment - | |||
| NCT00324740 Details | 2021-02-23 Interventional | 1/2 | 14 | Isotretinoin Vorinostat Carcinoma, Rena… Recurrent Renal… Stage III Renal… Stage IV Renal … | - - | |||
| NCT03696212 Details | 2021-02-21 Interventional | 1/2 | 18 | Pembrolizumab Adenocarcinoma Adenocarcinoma … Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Based on the totality of the generated combined safety and efficacy data in the interim period,
the company decided to terminate the combination study in NSCLC patients. There are no subjects
on study drug at this time or in the EOT Follow-up period. - | |||
| NCT03490942 Details | 2021-02-21 Interventional | 2 | 49 | Glucagon Glucagon-Like P… Diabetes Mellit… Diabetes Mellit… Hypoglycemia Hypoglycemia Un… | Primary endpoint was not met - |